Media
-
Oct 12, 2020Transaction creates a stronger, more efficient company
CARLSBAD, Calif., October 12, 2020 / PRNewswire/ – Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea...
-
Sep 18, 2020National Institute for Health and Care Excellence (NICE) issues a positive recommendation for volanesorsen to treat adults with Familial Chylomicronaemia Syndrome (FCS)
LONDON, UK, September 18, 2020 – Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc. (NASDAQ: AKCA), announced today that the National Institute for Health and Care Excellence...
-
Aug 31, 2020Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash
CARLSBAD, Calif., and BOSTON, August 31, 2020 – Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a...
-
Aug 29, 2020Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant, dose-dependent reductions in triglyceride levels, ANGPTL3 and additional lipid parameters compared to placebo
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data from the Phase 2 clinical trial...
-
Aug 29, 2020Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent reductions in triglyceride levels, apoC-III, and significant reductions in atherogenic lipoproteins
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data today from the Phase 2 study of...
-
Aug 24, 2020Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2...
-
Aug 18, 2020Data presentation will highlight efficacy, safety and tolerability of investigational medicine in patients with hypertriglyceridemia and cardiovascular disease
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 study...
-
Aug 13, 2020WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in Europe
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the German Association of Statutory Sick Funds has agreed upon new pricing...
-
Aug 4, 2020Global Net Product Revenues of $16 Million, an Increase of 66% Year-Over-Year
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare...
-
Jul 22, 2020TEGSEDI is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Austria for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of Austrian Social Security Institutions (Dachverband...
-
Jul 21, 2020Webcast scheduled for Tuesday, August 4 at 4:30 p.m. Eastern Time
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time...
-
Jul 20, 2020Dr. Christophe Hotermans joins company, with a decade of clinical practice and 12 years of experience in global biotechnology sector
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D., Ph.D., has joined the company as senior vice...
-
Jul 9, 2020Dr. William Andrews brings two decades of global industry experience, including more than 13 years in rare diseases and seven product launches
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joined the company as chief medical officer...
-
Jun 29, 2020Berns brings more than 20 years of experience in life sciences sector
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Tracy Palmer Berns has joined the company as chief compliance officer. In...
-
Jun 17, 2020
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases,...
-
Jun 9, 2020Dr. Kia Motesharei joins from Merck KGaA, bringing more than 20 years of experience in the pharmaceutical and biotechnology industry
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei, Ph.D., has joined the company as Senior Vice President of...
-
Jun 8, 2020TEGSEDI is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Italy for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that AIFA, or The Italian Medicines Agency, has granted approval for the...
-
Jun 1, 2020TEGSEDI is first antisense oligonucleotide medicine available to patients in Portugal for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the Portuguese Medicine Regulatory Authority (INFARMED) has granted approval for...
-
May 28, 2020Results from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen) experienced sustained improvements in measures of neuropathic progression at 39 months of therapy compared to the natural history of the disease
BOSTON and CARLSBAD, Calif., May 28, 2020 - Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
-
May 18, 2020Michael D. Price brings more than 25 years of experience in the pharmaceutical industry, including in the rare disease sector
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and...
-
May 14, 2020TEGSEDI is the first antisense medicine available to patients in Spain for at-home subcutaneous injection
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the...
-
May 13, 2020
OTTAWA, ON., - May 13, 2020 (CNW) – Akcea Therapeutics Canada, Inc., a subsidiary of Akcea Therapeutics, Inc. (NASDAQ: AKCA), today announced that it has concluded its negotiation with the...
-
May 7, 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief...
-
May 5, 2020Achieved First Quarter 2020 Global Net Product Revenues of $15 Million
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare...
-
Apr 21, 2020Webcast scheduled for Tuesday, May 5 at 4:30 p.m. Eastern Time
BOSTON, April 21, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on...
